Charles River Laboratories International, Inc. (CRL) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of anima...
Charles River Laboratories International, Inc. (CRL) currently trades at a P/E ratio of 18.95 (historical range: 17.84–63.26, median: 24.70), placing it at the 2th percentile — cheap relative to its history, P/S ratio of 3.58 (range: 1.26–7.88, 87th percentile — expensive relative to its history), EV/EBITDA of 30.51 (range: 16.71–164.14, 68th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Charles River Laboratories International, Inc.'s P/E ratio has contracted by 20% over the observed period (from an average of 29.8 to 23.8).
Charles River Laboratories International, Inc. trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 18.95 | 24.70 | 2th | cheap relative to its history |
| P/S Ratio | 3.58 | 2.61 | 87th | expensive relative to its history |
| EV/EBITDA | 30.51 | 23.30 | 68th | above its historical average |
| FCF Yield | 2.59% | 3.47% | 14th | expensive relative to its history |
Charles River Laboratories International, Inc. (CRL) Valuation & P/E History
Charles River Laboratories International, Inc. (CRL) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry currently trading at $300.15 with a market capitalization of $14.3 billion. This page provides historical valuation analysis for CRL based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 18.95 is below the historical median of 24.70, placing CRL at the 2th percentile of its valuation range. The P/S ratio of 3.58 compares to a median of 2.61.
CRL Valuation Metrics & Historical Range
The valuation table above shows Charles River Laboratories International, Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether CRL is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests CRL is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Charles River Laboratories International, Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is CRL Overvalued or Undervalued?
Charles River Laboratories International, Inc. trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 52 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive CRL is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full CRL analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.CRL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.